Literature DB >> 7845323

Cisplatin nephrotoxicity.

K B Meyer1, N E Madias.   

Abstract

Cisplatin treatment causes tubulointerstitial injury to the kidneys. Common clinical syndromes associated with its use include acute renal failure and a magnesium wasting state. Routine fluid infusion therapy has markedly reduced the incidence of acute renal failure. However, methodologic limitations of most recent studies preclude confident conclusions regarding long-term effects of cisplatin treatment on renal function. Experimental and clinical evidence suggests that sulfhydryl metabolism and oxidative stress are central to cisplatin renal injury. Both in animals and humans, a variety of agents appear to alter renal uptale of cisplatin and its hemodynamic consequences, thus modulating nephrotoxicity. Thiosulfates and related agents have received most study. Other agents examined have included calcium channel blockers, bismuth, selenium, glycine, cimetidine, and probenecid.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7845323

Source DB:  PubMed          Journal:  Miner Electrolyte Metab        ISSN: 0378-0392


  25 in total

Review 1.  Chemotherapy-associated renal dysfunction.

Authors:  Vaibhav Sahni; Devasmita Choudhury; Ziauddin Ahmed
Journal:  Nat Rev Nephrol       Date:  2009-06-30       Impact factor: 28.314

2.  Safety of a short hydration method for cisplatin administration in comparison with a conventional method-a retrospective study.

Authors:  Emiko Sakaida; Shunichiro Iwasawa; Ryota Kurimoto; Takahiro Ebata; Chiaki Imai; Tomoko Oku; Ikuo Sekine; Yuji Tada; Koichiro Tatsumi; Yuichi Takiguchi
Journal:  Jpn J Clin Oncol       Date:  2016-01-10       Impact factor: 3.019

3.  Association between eIF3α polymorphism and severe toxicity caused by platinum-based chemotherapy in non-small cell lung cancer patients.

Authors:  Xiaojing Xu; Lifang Han; Li Duan; Yingchun Zhao; Huaping Yang; Boting Zhou; Rui Ma; Ruixia Yuan; Honghao Zhou; Zhaoqian Liu
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

4.  Hyperthermia generated with ferucarbotran (Resovist®) in an alternating magnetic field enhances cisplatin-induced apoptosis of cultured human oral cancer cells.

Authors:  Itaru Sato; Masanari Umemura; Kenji Mitsudo; Mitomu Kioi; Hideyuki Nakashima; Toshinori Iwai; Xianfeng Feng; Kayoko Oda; Akiyoshi Miyajima; Ayako Makino; Maki Iwai; Takayuki Fujita; Utako Yokoyama; Satoshi Okumura; Motohiko Sato; Haruki Eguchi; Iwai Tohnai; Yoshihiro Ishikawa
Journal:  J Physiol Sci       Date:  2014-03-12       Impact factor: 2.781

Review 5.  Testicular cancer survivorship: research strategies and recommendations.

Authors:  Lois B Travis; Clair Beard; James M Allan; Alv A Dahl; Darren R Feldman; Jan Oldenburg; Gedske Daugaard; Jennifer L Kelly; M Eileen Dolan; Robyn Hannigan; Louis S Constine; Kevin C Oeffinger; Paul Okunieff; Greg Armstrong; David Wiljer; Robert C Miller; Jourik A Gietema; Flora E van Leeuwen; Jacqueline P Williams; Craig R Nichols; Lawrence H Einhorn; Sophie D Fossa
Journal:  J Natl Cancer Inst       Date:  2010-06-28       Impact factor: 13.506

6.  Sitagliptin exerts anti-apoptotic effect in nephrotoxicity induced by cisplatin in rats.

Authors:  Rehab S Abdelrahman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-04-05       Impact factor: 3.000

7.  Cisplatin-induced apoptosis in p53-deficient renal cells via the intrinsic mitochondrial pathway.

Authors:  Man Jiang; Cong-Yi Wang; Shuang Huang; Tianxin Yang; Zheng Dong
Journal:  Am J Physiol Renal Physiol       Date:  2009-03-11

8.  Antineoplastic drug, carboplatin, protects mice against visceral leishmaniasis.

Authors:  Tejinder Kaur; Prerna Makkar; Kulbir Randhawa; Sukhbir Kaur
Journal:  Parasitol Res       Date:  2012-09-09       Impact factor: 2.289

9.  Protection against cisplatin-induced nephrotoxicity in mice by Curcuma comosa Roxb. ethanol extract.

Authors:  Surawat Jariyawat; Pranida Kigpituck; Kanoknetr Suksen; Aporn Chuncharunee; Arusa Chaovanalikit; Pawinee Piyachaturawat
Journal:  J Nat Med       Date:  2009-06-18       Impact factor: 2.343

Review 10.  Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity.

Authors:  G R Matzke; R F Frye
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.